MR CLEAN MED
MR CLEAN-MED is a Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands investigating the effect of periprocedural MEDication: heparin, antiplatelet agents, both or neither. This trial is designed to answer the question if periprocedural administration of antithrombotic drugs can further improve the beneficial effect of acute endovascular thrombectomy for ischemic stroke.
The left hand menu helps you to navigate through this website and access more information about the trial.
Final patient included in the MR CLEAN MED
Between January 22th, 2018, and January 27th, 2021, we randomly assigned 663 patients; of whom, 628 (95%) provided deferred consent or died before consent could be asked and were included in the modified intention-to-treat population. On Feb 4, 2021, after unblinding and analysis of the data, the trial steering committee permanently stopped patient recruitment and the trial was stopped for safety concerns.
Results of the MR CLEAN-MED trial have been published in the Lancet in March 2022: https://www.sciencedirect.com/science/article/pii/S0140673622000149?via%3Dihub
Kind regards,
MR CLEAN-MED executive committee on behalf of the CONTRAST consortium:
Diederik Dippel, Aad van der Lugt, Rob van de Graaf, Bob Roozenbeek, Adriaan van Es, Heleen den Hertog, Julie Staals, Sjoerd Jenniskens, Lukas van Dijk